查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1837125

按器官类型、产品类型、捐赠者类型、手术类型和最终用户分類的移植市场 - 2025-2032 年全球预测

Transplantation Market by Organ Type, Product Type, Donor Type, Procedure Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，移植市场规模将成长至 609.8 亿美元，复合年增长率为 8.78%。

主要市场统计数据
基准年2024年 310.9亿美元
预计2025年 338亿美元
预测年份：2032年 609.8亿美元
复合年增长率（%） 8.78%

简要介绍临床创新、保存技术和程序转变如何重塑移植护理服务和商业性优先事项。

移植医学正处于关键的十字路口，外科技术、生物技术和器官保存方法的进步正在重新定义临床可能性。近期灌注和器官保存的创新，以及强化的免疫抑制方案，正在扩大移植的窗口，并使更复杂的手术成为可能。同时，捐赠者管理的转变以及微创和机器人技术的兴起正在改变医疗保健途径，迫使医院系统和医疗服务提供者重新思考其物流、采购和培训框架。

本报告整合了临床、技术、监管和付款方的动态，呈现了统一的高阶主管观点。报告重点介绍了产品系列（从导管、移植物和缝合线等耗材，到监测和灌注系统等设备，再到人工器官和血管移植物等植入）如何与不断变化的手术选择和供体特征相互影响。本书将门诊手术中心、医院和专科诊所的营运现状与临床结果和患者可近性的更广泛趋势联繫起来。最后，本引言将移植定位为临床复杂性与商业性机会交会的领域，为后续的详细分析奠定了基础。

手术方法、器官保存科学和以结果为中心的报销模式的转变如何改变移植生态系统

器官移植领域正在经历一场变革性的转变，这正在重新调整临床、技术应用和政策环境的竞争优势。临床上，由于希望降低手术全期併发症发生率并加快復健速度，手术方式明显从传统的开放性手术转向机器人辅助和腹腔镜技术。这一趋势的动力在于对免疫抑制精准管理的日益重视，以及旨在降低排斥反应并减轻长期副作用的新药物和联合策略。

技术变革同样意义重大。器官灌注和保存方案的日趋成熟正在提高器官存活率，而监测设备的进步则使更细緻的手术全期和移植后管理成为可能。同时，从先进的血管移植物到新型人工器官原型，植入正从概念发展到临床可行性，促使人们重新思考治疗途径。监管和报销环境正在适应这些技术创新，支付方和医疗保健系统越来越重视患者治疗效果和总护理成本的显着改善。总而言之，这些力量并非渐进式的；它们正在重塑采购重点、临床团队能力以及医疗服务提供者和供应商之间的长期策略蓝图。

评估 2025 年美国关税调整对器官移植供应链和采购弹性的营运和策略影响

2025年美国关税政策的变化给整个移植供应链带来了显着压力，影响了筹资策略、供应商关係和成本结构。某些进口零件和原材料的关税上调，增加了设备、耗材和植入製造商的到岸成本，迫使采购团队重新考虑供应商多元化和近岸外包的选择。这些变化也对库存管理和前置作业时间缓衝产生了连锁反应，因为医疗保健提供者需要在成本控制和保持对时间敏感的程序的连续性护理需求之间取得平衡。

作为应对措施，许多製造商加快了关键製造流程的本地化步伐，或寻找不易受关税波动影响的替代来源。临床和供应链领导者透过加强需求预测和协商强调韧性的服务水准协议来适应变化。此外，人们对基于价值的合约和捆绑支付结构重新产生了兴趣，这些结构可以吸收意外的成本压力，同时协调相关人员之间的奖励机制。虽然法规合规性和品质保证仍然至关重要，但关税上调引发了对供应韧性和策略采购的更广泛重新评估，这将影响未来的供应商选择和合作模式。

整合细分智能，将临床需求按器官、产品层次、捐赠途径、程序偏好和护理环境联繫起来，以提供策略优先排序信息

策略优先排序是基于对特定器官临床需求、产品层级、捐赠途径、手术选择和医疗环境的综合考量。依器官类型分析显示，心臟、肠道、肾臟、肝臟、肺臟和胰臟移植的临床优先顺序和设备需求有显着差异。例如，器官特定的保存要求和术后监测方案决定了产品需求和临床工作流程。从产品类型的角度来看，生态系涵盖导管、移植物和缝合线等耗材；监测设备、灌注设备和保存液等设备；包括人工器官和血管移植物在内的植入；以及抗增殖药物、钙调磷酸酶抑制剂、Calcineurin固醇和mTOR抑制剂等药物。此产品层级结构突显了渐进式创新和供应限制对营运影响最大的领域。

将捐赠者类型细分为死者捐赠途径和活体捐赠途径，每种途径都需要不同的物流和伦理考量，从而影响采购时间表、知情同意流程和术前优化。按手术类型细分，可以揭示与腹腔镜手术、开放式手术和机器人手术相关的不同资源状况和培训需求，从而改变资本规划和手术全期人员配置模式。最后，将门诊手术中心、医院和专科诊所的最终用户细分，可以说明医疗保健环境如何影响新技术的采用速度、采购週期以及与现有临床网路的整合。整合这些视角，相关人员可以製定反映临床细微差别和营运现实的策略，而不是一刀切的假设。

区域战略观点反映了美洲、欧洲、中东和非洲以及亚太地区的临床能力、法律规范和采购规范的差异

区域动态影响整个移植领域的采用轨迹、监管格局和伙伴关係机会。在美洲，临床卓越中心通常会推动先进器官保存系统和机器人技术的早期采用，而采购模式因公立和私立支付机构而异，从而影响采购週期和合约结构。欧洲、中东和非洲是一个多元化的地区，监管协调、基础设施差异以及器官共用协议的跨境合作既创造了机会，也带来了营运复杂性。该地区通常强调多中心註册和指南协调，以改善疗效。

亚太地区的特点是外科手术能力的快速投入、临床研究活动的活性化以及本地製造能力的提升，这些因素可能重塑全球供应关係。在每个地区，国家在报销框架、劳动力发展管道和捐赠者登记方面的政策都会影响新技术从核准到常规应用的速度。因此，一个地区成功的商业策略往往需要重新调整，以应对另一个地区采购规范、监管预期和临床实践模式的差异，因此，制定符合区域情况的蓝图对国际参与者至关重要。

设备製造商、生物製药公司和专业创新者之间的竞争与伙伴关係动态塑造了移植产品和服务的未来

移植医学领域的竞争态势并非由单一主导企业决定，而更取决于由设备製造商、製药公司、医院和利基市场创新者组成的生态系统的协同作用。现有的医疗设备製造商继续利用其规模、监管经验和分销网络，将监测系统、灌注平台和植入式可用技术商业化。生物製药公司正专注于下一代免疫抑制方案和辅助性治疗，以延长移植器官的寿命并提高患者的生活品质。同时，规模较小的专业公司和学术衍生公司正在为器官保存化学、生物工程移植材料和人工器官开发等领域带来颠覆性创新。

临床中心与产业之间的合作加速了真实世界证据的生成，并支持了付款人的参与。併购通常源自于整合互补能力的愿望，例如将设备平台与软体支援的监控相结合，或为更广泛的外科产品组合添加独特的储存解决方案。为了实现差异化，各公司正在投资于减少临床摩擦的服务，例如培训计划、全面的维护以及用于手术全期协调的数位化工具。总体而言，那些将临床提案主张与营运支援和持久的报销策略相结合的组织正在取得成功。

为高阶主管提供以行动为重点的策略性倡议，以增强供应弹性、加速临床应用，并使价值交付与移植护理报销保持一致

移植产业领导者应采取有针对性的策略，以增强韧性、加速临床应用并协调相关人员的奖励。首先，优先考虑供应链多元化，并认证关键零件的本地製造能力，以减轻关税波动和对单一供应商的依赖。其次，投资临床医生培训计画和临床证据生成，以证明患者治疗效果改善、总事件成本降低，并促进与付款人的建设性对话。第三，设计配套服务，将设备、储存解决方案、临床培训和术后监测相结合，以简化采购并为医院和专科诊所提供可衡量的价值。

同时，高阶主管应与高绩效移植中心建立策略合作关係，共同开发和检验新技术，以加快其应用速度并形成令人信服的价值叙事。引入数位化工具，加强手术全期协调和远端监控，以减少併发症并有效利用有限的专家资源。最后，积极与监管机构和报销机构合作，制定政策框架，以认可先进器官保存技术和综合护理模式的临床和经济效益。透过实施这些建议，组织可以将临床创新转化为永续的商业性优势。

一种透明的调查方法，融合了文献综述、专家访谈和资料三角测量，为临床和商业领域提供有效、可操作的见解

本研究结合定性和定量数据，结合系统性文献研究、专家访谈和跨部门数据三角检验，建构了器官移植生态系统的整体情况。调查方法首先全面回顾同侪审查的临床研究、监管申报和指南更新，以建立临床和科学基础。此外，还对移植外科医生、采购主管、医院管理人员和行业高管进行了结构化访谈，以了解操作细节、未满足的需求和应用障碍。

分析了包括设备註册、临床试验库和公共文件在内的二手信息，以检验趋势并绘製技术就绪水平图。应用三角测量技术来协调不同资讯来源之间的差异，并透过敏感度检查确保操作性解读在不同地区和医疗机构之间具有稳健性。最后，应用细分框架，根据器官类型、产品类型、供体途径、程序类型和最终用户情况整合洞察，从而能够根据不同相关人员的优先事项制定切实可行的建议。在整个过程中，我们始终遵循伦理研究实务和资料完整性标准指南证据的选择和整合。

综合可操作的结论，强调决定移植临床应用、营运弹性和商业性成功的趋同驱动因素

总而言之，移植医学正处于曲折点，技术进步、不断变化的程序规范和不断发展的政策框架正在汇聚，创造新的临床和商业性轨迹。器官特异性临床挑战、包括耗材、器械、植入和药品在内的多样化产品组合以及多样化的供体和手术环境的相互作用，凸显了差异化策略的必要性。投资于弹性供应链、证据产生、临床医生参与和整合服务模式的组织将处于有利地位，能够将创新转化为持续的临床影响。

展望未来，成功的关键在于驾驭区域监管多样性，妥善处理采购和报销动态，并建立伙伴关係以加速现实世界的推广应用。透过专注于以患者为中心的成果、营运效率和协作价值交付，相关人员可以建立一个移植生态系统，改善移植的可近性、疗效和长期移植物存活率，同时建立永续的商业性成长之路。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 扩大机器灌注技术的使用以提高供体器官的活力
  • 加大异种移植研究力度，解决器官短缺问题
  • 将人工智慧演算法整合到术前供体器官匹配工作流程中
  • 加强对细胞和基因编辑移植安全监测框架的监管
  • 利用区块链提高透明度的去中心化器官共用网路的出现
  • 利用去细胞化和再细胞化方法开发生物工程器官

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章 器官移植市场（依器官类型）

  • 心
  • 肠子
  • 肾
  • 肝
  • 肺
  • 胰臟

第九章 移植市场（依产品类型）

  • 耗材
    • 导管
    • 接枝
    • 缝合线
  • 装置
    • 监控设备
    • 灌注装置
    • 保存液
  • 植入
    • 人造器官
    • 血管移植物
  • 製药
    • 抗增生药物
    • Calcineurin抑制剂
    • 皮质类固醇
    • mTOR抑制剂

第 10 章 器官移植市场（依捐赠者类型）

  • 已故捐赠者
  • 活体捐赠者

第十一章 移植市场（依手术类型）

  • 腹腔镜
  • 打开
  • 机器人

第十二章 移植市场（依最终用户划分）

  • 门诊手术中心
  • 医院
  • 专科诊所

第十三章 器官移植市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 器官移植市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国移植市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Novartis AG
    • F. Hoffmann-La Roche AG
    • Astellas Pharma Inc.
    • Pfizer Inc.
    • Johnson & Johnson
    • Bristol-Myers Squibb Company
    • Sanofi SA
    • Merck KGaA
    • Teva Pharmaceutical Industries Ltd.
    • Baxter International Inc.
Product Code: MRR-031685195793

The Transplantation Market is projected to grow by USD 60.98 billion at a CAGR of 8.78% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 31.09 billion
Estimated Year [2025] USD 33.80 billion
Forecast Year [2032] USD 60.98 billion
CAGR (%) 8.78%

A concise primer on how clinical innovations, preservation technologies, and procedural shifts are reshaping transplantation care delivery and commercial priorities

Transplantation medicine is at a pivotal juncture, driven by advances in surgical techniques, biotechnologies, and organ preservation methods that are redefining clinical possibilities. Recent innovations in perfusion and preservation, together with enhanced immunosuppressive regimens, have extended viable windows for transplantation and enabled more complex procedures. Concurrently, shifts in donor management and the rise of minimally invasive and robotic approaches are altering care pathways, requiring hospital systems and suppliers to rethink logistics, procurement, and training frameworks.

This report synthesizes clinical, technological, regulatory, and payer-facing dynamics to present an integrated executive perspective. It emphasizes how product portfolios-from consumables such as catheters, grafts, and sutures to devices including monitoring and perfusion systems, and implants like artificial organs and vascular grafts-interact with evolving procedural choices and donor profiles. The narrative connects operational realities in ambulatory surgical centers, hospitals, and specialty clinics with broader trends in clinical outcomes and patient access. Ultimately, this introduction frames transplantation as a sector with intersecting clinical complexity and commercial opportunity, setting the stage for the deeper analyses that follow.

How shifts in surgical approaches, organ preservation science, and outcome-focused reimbursement models are collectively transforming the transplantation ecosystem

The transplantation landscape is experiencing transformative shifts across clinical practice, technology adoption, and policy environments that together recalibrate competitive advantage. Clinically, there is a clear movement from traditional open procedures to robotic-assisted and laparoscopic techniques, driven by the desire to reduce perioperative morbidity and accelerate recovery. This trend is accompanied by a growing emphasis on precision management of immunosuppression, where newer agents and combination strategies aim to reduce rejection while mitigating long-term adverse effects.

Technological shifts are equally consequential. The maturation of organ perfusion and preservation solutions has improved organ viability, while advances in monitoring devices enable more granular perioperative and post-transplant management. At the same time, implants-ranging from advanced vascular grafts to nascent artificial organ prototypes-are progressing from concept to clinical feasibility, prompting re-examination of care pathways. Regulatory and reimbursement environments are adapting to these innovations, with payers and health systems increasingly rewarding demonstrable improvements in patient outcomes and total cost of care. Taken together, these forces are not incremental; they are reshaping procurement priorities, clinical team competencies, and long-term strategic roadmaps across providers and suppliers.

Assessment of the operational and strategic consequences of United States tariff adjustments in 2025 on transplantation supply chains and procurement resilience

Tariff policy changes in the United States in 2025 introduced discrete pressures across the transplantation supply chain, influencing sourcing strategies, supplier relationships, and cost structures. Increased duties on certain imported components and raw materials have raised landed costs for manufacturers of devices, consumables, and implants, prompting procurement teams to revisit supplier diversification and nearshoring options. These dynamics have had ripple effects on inventory practices and lead-time buffers, as healthcare providers balance cost containment with the imperative to maintain continuity of care for time-sensitive procedures.

In response, many manufacturers accelerated efforts to localize critical manufacturing steps or to qualify alternative sources that reduce exposure to tariff volatility. Clinical and supply chain leaders adapted by strengthening demand forecasting and by negotiating service-level agreements that emphasize resilience. Additionally, there has been renewed interest in value-based contracting and bundled payment structures that can absorb episodic cost pressures while aligning incentives across stakeholders. While regulatory compliance and quality assurance remain paramount, the tariffs catalyzed a broader reassessment of supply resilience and strategic procurement that will influence supplier selection and partnership models going forward.

Integrated segmentation intelligence that connects organ-specific clinical needs, product hierarchies, donor pathways, procedural choices, and care settings to inform strategic prioritization

A nuanced understanding of the transplantation landscape requires integrating insights across five segmentation lenses that together capture clinical, product, donor, procedural, and end-user variability. When analyzed by organ type, clinical priorities and device needs differ substantially between heart, intestine, kidney, liver, lung, and pancreas transplantation; for example, organ-specific preservation requirements and post-operative monitoring protocols shape product demand and clinical workflows. From a product type perspective, the ecosystem spans consumables such as catheters, grafts, and sutures; devices including monitoring devices, perfusion devices, and preservation solutions; implants covering artificial organs and vascular grafts; and pharmaceuticals comprising antiproliferative agents, calcineurin inhibitors, corticosteroids, and mTOR inhibitors. This product hierarchy underscores where incremental innovation and supply constraints exert the greatest operational impact.

Donor type segmentation divides practice between deceased donor and living donor pathways, each presenting distinct logistical and ethical considerations that affect procurement timelines, consent processes, and preoperative optimization. Procedure type segmentation highlights the differing resource profiles and training demands associated with laparoscopic, open, and robotic procedures, which in turn alter capital planning and perioperative staffing models. Finally, end-user segmentation across ambulatory surgical centers, hospitals, and specialty clinics demonstrates how care setting influences adoption speed for new technologies, procurement cycles, and integration with existing clinical networks. Synthesizing these lenses allows stakeholders to tailor strategies that reflect clinical nuance and operational realities rather than one-size-fits-all assumptions.

Regional strategic perspectives reflecting how clinical capacity, regulatory frameworks, and procurement norms vary across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape adoption trajectories, regulatory touchpoints, and partnership opportunities across the transplantation landscape. In the Americas, clinical centers of excellence often drive early implementation of advanced preservation systems and robotic techniques, while procurement models vary between public and private payers, influencing purchasing cycles and contracting structures. Europe, the Middle East & Africa present a heterogeneous mosaic in which regulatory alignment, infrastructure disparities, and cross-border collaboration on organ sharing protocols create both opportunities and operational complexity; this region frequently emphasizes multicenter registries and guideline harmonization to elevate outcomes.

Asia-Pacific is characterized by rapid investment in surgical capacity, growing clinical research activity, and increasing local manufacturing capabilities that can reshape global supply relationships. Across all regions, reimbursement frameworks, workforce training pipelines, and national policies on donor registries influence how quickly new technologies move from approval to routine use. Consequently, commercial strategies that succeed in one geography often require recalibration to accommodate differences in procurement norms, regulatory expectations, and clinical practice patterns in another, making regionally informed roadmaps essential for international players.

Competitive and partnership dynamics across device makers, biopharmaceutical firms, and specialist innovators that are shaping the future of transplantation product and service offerings

Competitive dynamics in transplantation are defined less by a single dominant player and more by ecosystem orchestration involving device manufacturers, pharmaceutical firms, hospitals, and niche innovators. Established medical device companies continue to leverage scale, regulatory experience, and distribution networks to commercialize monitoring systems, perfusion platforms, and implantable technologies. Biopharmaceutical organizations focus on next-generation immunosuppressive regimens and adjunct therapies that improve graft longevity and patient quality of life. Meanwhile, smaller, specialized firms and academic spinouts contribute disruptive innovations in preservation chemistry, bioengineered graft materials, and artificial organ development.

Partnership strategies are increasingly central to competitive advantage; collaborations between clinical centers and industry accelerate real-world evidence generation and support payer engagement. Mergers and acquisitions are often driven by the desire to integrate complementary capabilities, such as combining device platforms with software-enabled monitoring or adding proprietary preservation solutions to a broader surgical portfolio. To differentiate, companies are investing in services that reduce clinical friction, including training programs, comprehensive maintenance, and digital tools for perioperative coordination. Overall, success favors organizations that align clinical value propositions with operational support and durable reimbursement strategies.

Action-centered strategic measures for executives to fortify supply resilience, accelerate clinical adoption, and align reimbursement with value delivery in transplantation

Leaders in the transplantation sector should pursue focused strategies that strengthen resilience, accelerate clinical adoption, and align stakeholder incentives. First, prioritize supply chain diversification and qualification of local manufacturing capacity for mission-critical components to mitigate exposure to tariff volatility and single-source dependencies. Second, invest in clinician training programs and clinical evidence generation that demonstrate improved patient outcomes and reduced total episode costs, facilitating more constructive payer conversations. Third, design bundled service offerings that combine devices, preservation solutions, clinical training, and post-operative monitoring to simplify procurement and deliver measurable value to hospitals and specialty clinics.

In parallel, executives should pursue strategic collaborations with high-performing transplant centers to co-develop and validate new technologies, supporting faster uptake and more persuasive value narratives. Embrace digital tools that enhance perioperative coordination and remote monitoring, as these can reduce complications and enable efficient use of limited specialist resources. Finally, maintain active engagement with regulators and reimbursement bodies to shape policy frameworks that recognize the clinical and economic benefits of advanced preservation technologies and integrated care models. By executing these recommendations, organizations can convert clinical innovation into sustainable commercial advantage.

Transparent research approach blending literature review, expert interviews, and data triangulation to produce validated, actionable insights across clinical and commercial domains

This research integrates qualitative and quantitative inputs to construct a holistic view of the transplantation ecosystem, combining systematic literature review, targeted expert interviews, and cross-functional data triangulation. The methodology began with an exhaustive review of peer-reviewed clinical studies, regulatory submissions, and guideline updates to establish the clinical and scientific foundation. This was complemented by structured interviews with transplant surgeons, procurement leaders, hospital administrators, and industry executives to capture operational nuances, unmet needs, and adoption barriers.

Secondary sources such as device registries, clinical trial repositories, and public policy documents were analyzed to validate trends and to map technology readiness levels. Triangulation techniques were applied to reconcile discrepancies across sources, and sensitivity checks ensured that operational interpretations were robust across geographies and care settings. Finally, segmentation frameworks were applied to align insights to organ type, product type, donor pathway, procedure type, and end-user context, enabling the development of actionable recommendations suited to different stakeholder priorities. Throughout, adherence to ethical research practices and data integrity standards guided evidence selection and synthesis.

Synthesis of actionable conclusions highlighting the converging drivers that will determine clinical adoption, operational resilience, and commercial success in transplantation

In conclusion, transplantation is poised at an inflection point where technological advances, shifting procedural norms, and evolving policy frameworks converge to create new clinical and commercial pathways. The interplay between organ-specific clinical challenges, a diverse product landscape encompassing consumables, devices, implants, and pharmaceuticals, and variable donor and procedural contexts underscores the need for differentiated strategies. Organizations that invest in resilient supply chains, evidence generation, clinician engagement, and integrated service models will be better positioned to translate innovation into sustained clinical impact.

Moving forward, success will depend on the ability to navigate regional regulatory heterogeneity, respond to procurement and reimbursement dynamics, and build partnerships that accelerate real-world adoption. By focusing on patient-centric outcomes, operational efficiency, and collaborative value delivery, stakeholders can contribute to a transplantation ecosystem that improves access, outcomes, and long-term graft survival while creating sustainable pathways for commercial growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing utilization of machine perfusion technologies to expand donor organ viability
  • 5.2. Rising adoption of xenotransplantation research to address critical organ shortages
  • 5.3. Integration of artificial intelligence algorithms in pre-operative donor organ matching workflows
  • 5.4. Growing regulatory focus on cell and gene edited graft safety monitoring frameworks
  • 5.5. Emergence of decentralized organ sharing networks leveraging blockchain for transparency
  • 5.6. Development of bioengineered organs using decellularization and recellularization methods

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transplantation Market, by Organ Type

  • 8.1. Heart
  • 8.2. Intestine
  • 8.3. Kidney
  • 8.4. Liver
  • 8.5. Lung
  • 8.6. Pancreas

9. Transplantation Market, by Product Type

  • 9.1. Consumables
    • 9.1.1. Catheters
    • 9.1.2. Grafts
    • 9.1.3. Sutures
  • 9.2. Devices
    • 9.2.1. Monitoring Devices
    • 9.2.2. Perfusion Devices
    • 9.2.3. Preservation Solutions
  • 9.3. Implants
    • 9.3.1. Artificial Organs
    • 9.3.2. Vascular Grafts
  • 9.4. Pharmaceuticals
    • 9.4.1. Antiproliferative Agents
    • 9.4.2. Calcineurin Inhibitors
    • 9.4.3. Corticosteroids
    • 9.4.4. Mtor Inhibitors

10. Transplantation Market, by Donor Type

  • 10.1. Deceased Donor
  • 10.2. Living Donor

11. Transplantation Market, by Procedure Type

  • 11.1. Laparoscopic
  • 11.2. Open
  • 11.3. Robotic

12. Transplantation Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Transplantation Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Transplantation Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Transplantation Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novartis AG
    • 16.3.2. F. Hoffmann-La Roche AG
    • 16.3.3. Astellas Pharma Inc.
    • 16.3.4. Pfizer Inc.
    • 16.3.5. Johnson & Johnson
    • 16.3.6. Bristol-Myers Squibb Company
    • 16.3.7. Sanofi S.A.
    • 16.3.8. Merck KGaA
    • 16.3.9. Teva Pharmaceutical Industries Ltd.
    • 16.3.10. Baxter International Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSPLANTATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSPLANTATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL TRANSPLANTATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TRANSPLANTATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS TRANSPLANTATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL TRANSPLANTATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. TRANSPLANTATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. TRANSPLANTATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TRANSPLANTATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TRANSPLANTATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TRANSPLANTATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSPLANTATION MARKET SIZE, BY HEART, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TRANSPLANTATION MARKET SIZE, BY HEART, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSPLANTATION MARKET SIZE, BY HEART, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TRANSPLANTATION MARKET SIZE, BY HEART, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSPLANTATION MARKET SIZE, BY HEART, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TRANSPLANTATION MARKET SIZE, BY HEART, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSPLANTATION MARKET SIZE, BY INTESTINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TRANSPLANTATION MARKET SIZE, BY INTESTINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSPLANTATION MARKET SIZE, BY INTESTINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TRANSPLANTATION MARKET SIZE, BY INTESTINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSPLANTATION MARKET SIZE, BY INTESTINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TRANSPLANTATION MARKET SIZE, BY INTESTINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSPLANTATION MARKET SIZE, BY KIDNEY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TRANSPLANTATION MARKET SIZE, BY KIDNEY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSPLANTATION MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TRANSPLANTATION MARKET SIZE, BY KIDNEY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSPLANTATION MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TRANSPLANTATION MARKET SIZE, BY KIDNEY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSPLANTATION MARKET SIZE, BY LUNG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TRANSPLANTATION MARKET SIZE, BY LUNG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSPLANTATION MARKET SIZE, BY LUNG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TRANSPLANTATION MARKET SIZE, BY LUNG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSPLANTATION MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TRANSPLANTATION MARKET SIZE, BY LUNG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSPLANTATION MARKET SIZE, BY PANCREAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TRANSPLANTATION MARKET SIZE, BY PANCREAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSPLANTATION MARKET SIZE, BY PANCREAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TRANSPLANTATION MARKET SIZE, BY PANCREAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSPLANTATION MARKET SIZE, BY PANCREAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TRANSPLANTATION MARKET SIZE, BY PANCREAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSPLANTATION MARKET SIZE, BY CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TRANSPLANTATION MARKET SIZE, BY CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSPLANTATION MARKET SIZE, BY CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TRANSPLANTATION MARKET SIZE, BY CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSPLANTATION MARKET SIZE, BY CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TRANSPLANTATION MARKET SIZE, BY CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TRANSPLANTATION MARKET SIZE, BY GRAFTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TRANSPLANTATION MARKET SIZE, BY GRAFTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRANSPLANTATION MARKET SIZE, BY GRAFTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TRANSPLANTATION MARKET SIZE, BY GRAFTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRANSPLANTATION MARKET SIZE, BY GRAFTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TRANSPLANTATION MARKET SIZE, BY GRAFTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRANSPLANTATION MARKET SIZE, BY SUTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TRANSPLANTATION MARKET SIZE, BY SUTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TRANSPLANTATION MARKET SIZE, BY SUTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TRANSPLANTATION MARKET SIZE, BY SUTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRANSPLANTATION MARKET SIZE, BY SUTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TRANSPLANTATION MARKET SIZE, BY SUTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TRANSPLANTATION MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TRANSPLANTATION MARKET SIZE, BY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TRANSPLANTATION MARKET SIZE, BY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRANSPLANTATION MARKET SIZE, BY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TRANSPLANTATION MARKET SIZE, BY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TRANSPLANTATION MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TRANSPLANTATION MARKET SIZE, BY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TRANSPLANTATION MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TRANSPLANTATION MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TRANSPLANTATION MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TRANSPLANTATION MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TRANSPLANTATION MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TRANSPLANTATION MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TRANSPLANTATION MARKET SIZE, BY PERFUSION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TRANSPLANTATION MARKET SIZE, BY PERFUSION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TRANSPLANTATION MARKET SIZE, BY PERFUSION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TRANSPLANTATION MARKET SIZE, BY PERFUSION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL TRANSPLANTATION MARKET SIZE, BY PERFUSION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL TRANSPLANTATION MARKET SIZE, BY PERFUSION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRESERVATION SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRESERVATION SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRESERVATION SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRESERVATION SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRESERVATION SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRESERVATION SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL TRANSPLANTATION MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL TRANSPLANTATION MARKET SIZE, BY IMPLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL TRANSPLANTATION MARKET SIZE, BY IMPLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL TRANSPLANTATION MARKET SIZE, BY IMPLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL TRANSPLANTATION MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL TRANSPLANTATION MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL TRANSPLANTATION MARKET SIZE, BY ARTIFICIAL ORGANS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL TRANSPLANTATION MARKET SIZE, BY ARTIFICIAL ORGANS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL TRANSPLANTATION MARKET SIZE, BY ARTIFICIAL ORGANS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL TRANSPLANTATION MARKET SIZE, BY ARTIFICIAL ORGANS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL TRANSPLANTATION MARKET SIZE, BY ARTIFICIAL ORGANS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL TRANSPLANTATION MARKET SIZE, BY ARTIFICIAL ORGANS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL TRANSPLANTATION MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL TRANSPLANTATION MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL TRANSPLANTATION MARKET SIZE, BY VASCULAR GRAFTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL TRANSPLANTATION MARKET SIZE, BY VASCULAR GRAFTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL TRANSPLANTATION MARKET SIZE, BY VASCULAR GRAFTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL TRANSPLANTATION MARKET SIZE, BY VASCULAR GRAFTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL TRANSPLANTATION MARKET SIZE, BY ANTIPROLIFERATIVE AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL TRANSPLANTATION MARKET SIZE, BY ANTIPROLIFERATIVE AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL TRANSPLANTATION MARKET SIZE, BY ANTIPROLIFERATIVE AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL TRANSPLANTATION MARKET SIZE, BY ANTIPROLIFERATIVE AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL TRANSPLANTATION MARKET SIZE, BY ANTIPROLIFERATIVE AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL TRANSPLANTATION MARKET SIZE, BY ANTIPROLIFERATIVE AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL TRANSPLANTATION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL TRANSPLANTATION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL TRANSPLANTATION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL TRANSPLANTATION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL TRANSPLANTATION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL TRANSPLANTATION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL TRANSPLANTATION MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL TRANSPLANTATION MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL TRANSPLANTATION MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL TRANSPLANTATION MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL TRANSPLANTATION MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL TRANSPLANTATION MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL TRANSPLANTATION MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL TRANSPLANTATION MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL TRANSPLANTATION MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL TRANSPLANTATION MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL TRANSPLANTATION MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL TRANSPLANTATION MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL TRANSPLANTATION MARKET SIZE, BY DECEASED DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL TRANSPLANTATION MARKET SIZE, BY DECEASED DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL TRANSPLANTATION MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL TRANSPLANTATION MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL TRANSPLANTATION MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL TRANSPLANTATION MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVING DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVING DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVING DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVING DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL TRANSPLANTATION MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL TRANSPLANTATION MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL TRANSPLANTATION MARKET SIZE, BY LAPAROSCOPIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL TRANSPLANTATION MARKET SIZE, BY LAPAROSCOPIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL TRANSPLANTATION MARKET SIZE, BY LAPAROSCOPIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL TRANSPLANTATION MARKET SIZE, BY LAPAROSCOPIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL TRANSPLANTATION MARKET SIZE, BY OPEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL TRANSPLANTATION MARKET SIZE, BY OPEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL TRANSPLANTATION MARKET SIZE, BY OPEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL TRANSPLANTATION MARKET SIZE, BY OPEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL TRANSPLANTATION MARKET SIZE, BY OPEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL TRANSPLANTATION MARKET SIZE, BY OPEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL TRANSPLANTATION MARKET SIZE, BY ROBOTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL TRANSPLANTATION MARKET SIZE, BY ROBOTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL TRANSPLANTATION MARKET SIZE, BY ROBOTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL TRANSPLANTATION MARKET SIZE, BY ROBOTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL TRANSPLANTATION MARKET SIZE, BY ROBOTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL TRANSPLANTATION MARKET SIZE, BY ROBOTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL TRANSPLANTATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL TRANSPLANTATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL TRANSPLANTATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL TRANSPLANTATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL TRANSPLANTATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL TRANSPLANTATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL TRANSPLANTATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL TRANSPLANTATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL TRANSPLANTATION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL TRANSPLANTATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL TRANSPLANTATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL TRANSPLANTATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL TRANSPLANTATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL TRANSPLANTATION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL TRANSPLANTATION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL TRANSPLANTATION MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL TRANSPLANTATION MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL TRANSPLANTATION MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL TRANSPLANTATION MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL TRANSPLANTATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL TRANSPLANTATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS TRANSPLANTATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS TRANSPLANTATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS TRANSPLANTATION MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS TRANSPLANTATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE TRANSPLANTATION MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE TRANSPLANTATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. AFRICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. AFRICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. AFRICA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. AFRICA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. AFRICA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. AFRICA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. AFRICA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 332. AFRICA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 333. AFRICA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 334. AFRICA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 335. AFRICA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 336. AFRICA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 337. AFRICA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 338. AFRICA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 339. AFRICA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 340. AFRICA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 341. AFRICA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 342. AFRICA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 343. AFRICA TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 344. AFRICA TRANSPLANTATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 345. ASIA-PACIFIC TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)

TABLE 3